Company
Headquarters: Shenyang, China
Employees: 1,102
CN¥14.67 Billion
CNY as of Jan. 1, 2025
US$2.01 Billion
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $216.79 B |
| EssilorLuxottica SA | $116.96 B |
| Becton, Dickinson and Company | $69.74 B |
| HOYA Corp | $45.26 B |
| Alcon Inc. | $41.55 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥1.80 B |
| EBITDA | CN¥416.0 M |
| Gross Profit TTM | CN¥1.14 B |
| Profit Margin | 19.34% |
| Operating Margin | 25.76% |
| Quarterly Revenue Growth | 30.50% |
Shenyang Xingqi Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300573 wb_incandescent